FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
27 March 2026 at 06:47
The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).